Verdiva Bio

Verdiva Bio is committed to developing next-generation therapies that offer more patient-friendly treatment options, helping patients with obesity, cardiometabolic disorders, and related complications achieve better outcomes. Verdiva's most advanced therapy is VRB-101, an oral GLP-1 peptide currently in clinical development, which has demonstrated first-in-class efficacy potential in a Phase 1 study conducted in Australia, confirming the feasibility of once-weekly dosing. The company is also developing a portfolio of amylin analog molecules, including oral and subcutaneous agonists, as well as other undisclosed programs with the potential to enhance efficacy, improve tolerability, and promote healthier weight loss. The Verdiva team will leverage emerging science in gut-brain biology and draw on their successful track record in drug development to advance new therapeutic options aimed at transforming the lives of millions of people worldwide who are affected by obesity.